Articles tagged with Monoclonal Antibodies
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
A clinical study in Birmingham has found that nipocalimab can improve the survival rate of unborn babies with rare fetal anaemia. The majority of pregnant patients who received nipocalimab gave birth at or after 32 weeks without needing an intrauterine transfusion, resulting in a perinatal survival rate of 92%.
A study published in the Journal of Clinical Immunology found alemtuzumab to be safe and effective in treating Asian patients with inborn errors of immunity after allogeneic hematopoietic cell transplantation. The drug was shown to improve overall survival rates, with 94.7% of patients surviving post-transplantation.
Crystallized monoclonal antibodies demonstrate improved viscosity levels, stability, and shelf-life under microgravity conditions. This process streamlines manufacturing and improves scalability for subcutaneous administration, offering greater patient convenience and compliance.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.
A Phase 1 clinical trial is underway to evaluate the safety and efficacy of an investigational monoclonal antibody targeting enterovirus D68 (EV-D68), a virus associated with severe respiratory and neurological diseases. The trial will assess the antibody's potency, duration of action, and optimal dose in healthy volunteers.
Researchers have discovered how a neutralizing antibody blocks measles virus infection by arresting the fusion process. The study's findings may also be relevant to other viruses with pandemic potential, such as Nipah and parainfluenza viruses.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers estimate that 32% of memory clinic attendees and 14% of specialist cognitive service patients are eligible for disease-modifying therapies. Biomarker testing is crucial to identify suitable patients, but only a minority have undergone tests.
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
Researchers report that dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in COPD patients with type 2 inflammation. The study's findings are promising for these patients, who have a high risk of exacerbations.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
An experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, lengthening their lifespan. The drug targets insulin-making beta cells directly and shields them from immune system attacks, raising the possibility of a new treatment for the autoimmune condition.
Cory Brooks has been appointed as the new Editor-in-Chief of the journal, bringing his expertise in structural biology and antibody research to the role. He aims to advance understanding of antibody therapeutics and promote sharing of research on hybridoma technology.
Researchers discovered two distinct sites on the EBV protein gp42 that can be targeted to prevent infection and cancer. Monoclonal antibody A10 provided nearly complete protection against EBV infection in mice.
Researchers at NIH have identified antibodies targeting a hard-to-spot region of the influenza virus's neuraminidase protein head, known as the NA dark side. These antibodies could be used to develop new vaccine and therapeutic strategies, providing protection against influenza viruses with drug-resistant mutations.
A monoclonal antibody, omalizumab, increased the tolerance threshold for multiple food allergens, allowing children to consume larger amounts without a reaction. The treatment showed significant benefits in reducing allergic reactions, particularly for peanut and egg, with potential protection against accidental exposure.
Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.
The FDA has approved omalizumab for the reduction of allergic reactions, including anaphylaxis, in adults and children aged 1 year and older with food allergy. The approval is based on data from a Phase 3 clinical trial sponsored by NIAID.
Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering have made significant breakthroughs in understanding how antibodies combat herpes simplex virus (HSV) infections. The study reveals that antibody effector functions play a critical role in protecting against HSV, which may lead to new treatments for n...
A multidisciplinary team created a new algorithm to provide optimal personalized treatment options for individuals with esophageal cancer. The framework uses various heterogeneous factors that facilitate the progression of the disease and demonstrated high accuracy in controlling esophageal cancer.
Early data from Luxembourg's national immunisation campaign against severe respiratory syncytial virus (RSV) in 2023 showed a decline in hospitalisations, especially among infants under six months old. The authors attributed this to the administration of a monoclonal antibody, nirsevimab, shortly after birth. Additionally, the mean age...
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
Researchers from Tokyo University of Science discovered that manipulating polyamines enhances the functional profiles of monoclonal antibodies. The study found that controlling polyamine levels increases IgG galactosylation, leading to improved therapeutic efficacy.
Researchers developed a novel platform to transport therapeutic antibodies across the blood-brain barrier using a biocompatible polymer. The method showed promising results in both in vitro and mouse-model experiments, suggesting enhanced brain delivery of cancer-fighting antibodies without inducing adverse effects.
A monoclonal antibody treatment increased food-allergic children and adolescents' tolerance to common foods, reducing allergic reactions. Omalizumab, approved for other indications, is being reviewed for a new indication based on the trial's interim analysis.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.
The European Union has approved vaccines for pregnant women and monoclonal antibodies to prevent respiratory syncytial virus (RSV) among young children. New sequencing tools have also been developed to track the genetic diversity of RSV and inform vaccine effectiveness and treatment strategies.
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
Researchers at Osaka University have developed a novel radioactive antibody that can diagnose and treat a deadly type of pancreatic cancer. The antibody targets glypican-1, a protein highly expressed in PDAC tumors, allowing for early detection and treatment with improved survival rates.
Researchers have developed a human vascular organoid model that accurately mimics the damage caused by SARS-CoV-2, revealing clues for a potential COVID-19 treatment. The study identified a long-acting monoclonal antibody targeting factor D as a promising approach to mitigate severe vascular damage and thrombosis associated with COVID-19.
A large international study led by Danish researchers may have brought us closer to a cure for HIV. The study found that patients who received monoclonal antibodies before pausing their regular treatment experienced a period of virus suppression, and some even saw their immune system partially or completely suppress the virus.
A weighted lottery system may favor allocation of COVID-19 monoclonal antibody to individuals in disadvantaged neighborhoods and those identifying as Black. However, this approach may also result in lower acceptance rates among Black individuals who receive the drug.
Patients with cancer had disparate COVID-19 mortality rates during the winter Omicron wave compared to the general US population. The study suggests that immune-evasive SARS-CoV-2 variants pose a significant threat, requiring prioritized efforts to prevent transmission.
A new article published in RadioGraphics warns of a potential side effect of novel Alzheimer's treatments: amyloid-related imaging abnormalities (ARIA). ARIA can cause swelling or bleeding in the brain and may be asymptomatic. Radiologists must monitor for ARIA to plan image monitoring per established guidelines.
Researchers at Duke University Medical Center developed a new monoclonal antibody that successfully prevented organ rejection in primates undergoing kidney and islet transplantations. The findings suggest a safer alternative to existing immunosuppressive drugs, reducing side effects and improving graft survival rates.
Researchers at OHSU identified a type of monoclonal antibody that can slow the progression of amyotrophic lateral sclerosis (ALS) by modulating immune cells. The study used a mouse model and confirmed results in human brains affected by ALS, revealing a promising potential treatment for this fatal neurodegenerative disease.
The American Academy of Neurology has developed an Emerging Issues in Neurology article providing timely guidance on new therapies for early Alzheimer's disease. The guidance explains the eligibility criteria, potential side effects, and limitations of these treatments, which are not a cure for the disease.
The latest Alzheimer's drug, donanemab, has shown encouraging results in slowing cognitive decline by 35% compared to placebo in patients with low-to-intermediate levels of tau. However, its effectiveness is limited for those with more advanced disease, and risks include serious side effects such as amyloid-related imaging abnormalities.
New research reveals low use of monoclonal antibodies and oral antiviral drugs in US nursing homes, despite high risk of resident populations. The study analyzed data from the Center for Disease Control and Prevention National Healthcare Safety Network during the COVID-19 pandemic.
The decision analytic model found monoclonal antibodies pre-exposure prophylaxis to be cost-effective for individuals at increased risk of severe COVID-19. The study suggests that lower drug prices and higher effectiveness could further increase the benefits of mAbs PrEP provision.
Researchers identified four therapeutic monoclonal antibody candidates that neutralized a range of SARS-CoV-2 variants. Prolonged exposure to the virus triggered somatic hypermutations, equipping these antibodies with an extensive binding interface.
COPD patients treated with dupilumab experienced rapid and sustained improvements in disease, as measured by reduced acute exacerbations, better lung function, and improved quality of life. This is the first biologic to show clinical outcomes improvement in COPD.
A clinical trial found that benralizumab effectively depleted eosinophils, but it did not alleviate symptoms or improve gut tissue health in patients with eosinophilic gastritis. The study's findings suggest a new therapeutic target for eosinophilic gastrointestinal diseases and highlight the need to reconsider remission definitions.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers at MIT have designed new 'smart' sutures that can deliver drugs or sense inflammation after surgery. The bioderived sutures use hydrogel coatings to detect early warning signs of complications, such as Crohn's disease, and can also release therapeutic molecules to promote healing.
A new immunotherapy treatment developed by UCF researchers uses targeted IL-2 to fight respiratory viral infections with improved outcomes in animal studies. The treatment promotes an antiviral inflammatory response and reduces bronchial inflammation.
Researchers have developed a new immunotherapy targeting tumour macrophages, which are immunosuppressive cells that weaken the immune system. The treatment, RImAb, reduces tumour growth and modifies the tumour microenvironment, offering potential for a new line of treatment for lung cancer patients.
A treatment combining two antibodies against SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death. The treatment was effective against the delta variant and appeared safe, with significantly lower reports of side effects compared to a placebo.
Researchers from Lund University have designed a cocktail of modified antibodies that tag the virus to be eliminated by the immune system. The study found that combining different combinations of these antibodies can improve their function, suggesting a potent clinical effect against SARS-CoV-2 and its variants.
Researchers developed a chelator-free-radiolabeled polymersome capable of long-term multiday PET imaging in vivo. The nanovesicle meets key requirements for targeted cancer therapy, including precision targeting, stable radiotracer binding, and biocompatibility.
Researchers at Weill Cornell Medicine have identified an antibody that blocks infection by all dominant COVID-19 variants, including Omicron. The discovery could lead to new antibody-based treatments and more effective vaccines.
A new study led by Brigham investigators found that people produce shared antibody responses to certain regions of the virus, leading to selective pressure and new variants. The team's findings have implications for our understanding of immunity and public health, particularly in terms of re-infection during the COVID-19 pandemic.
Researchers analyzed 2,571 patients treated with monoclonal antibodies and found a 39% reduced risk of hospitalization or death compared to non-treated peers. The study also showed greater benefit in patients with immunocompromising conditions and those treated earlier during the pandemic.
Researchers found that using monoclonal antibodies within two days of a COVID-19 diagnosis reduced the risk of hospitalization or death by 39% compared to those who did not receive treatment. This finding suggests that early treatment with monoclonal antibodies significantly reduced the severity of COVID-19.
Researchers have found lab-made antibodies that can strengthen the body's fight against yellow fever, a disease with no current treatment. The monoclonal antibody infusions were able to remove all signs of infection from research animals, offering potential hope for a cure.
A new study describes an optimized method for isolating and identifying nanobodies targeting SARS-CoV-2, which could lead to the development of effective therapies. The approach uses a yeast display method, reducing costs and time required for screening nanobody libraries.
Researchers have identified a new target for COVID-19 treatment: the mammalian SWI/SNF chromatin remodeling complex. Disrupting this complex's activity blocks ACE2 receptor production, making cells resistant to SARS-CoV-2 infection. This approach offers a promising novel method for combating drug-resistant variants.
Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.